# Celator Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/celator-pharmaceuticals

- Industry: Biotechnology
- Headquarters: Princeton, US
- Website: www.celatorpharma.com
- Total disclosed funding: $97M
- Latest round: Series D (Dec 15, 2011)
- Investors on record: 8

## About

Celator Pharmaceuticals focuses on developing innovative therapies to treat cancer, utilizing proprietary drug delivery technologies to enhance the efficacy of established treatments.Celator Pharmaceuticals, Inc. specializes in cancer treatment development. The company was founded in 2000 and is headquartered in Princeton, US. In June 2016, Jazz Pharmaceuticals acquired Celator Pharmaceuticals for USD 30.25 per share. The company has secured a total of USD 1,500.00 mn through funding rounds, with the latest being a Trade Sale in June 2014 involving Jazz Pharmaceuticals, Inc. The company has completed 11 different deals since its inception.Celator Pharmaceuticals develops innovative medicines aimed at improving cancer treatment outcomes. Its primary focus is on delivering novel therapies that optimize existing treatments through advanced drug delivery systems, potentially improving patient responses and reducing side effects.In 2015, Celator Pharmaceuticals reported an EBITDA of USD -17,997,521, reflecting the company's ongoing investments in research and development as it seeks to advance its innovative therapies into the market.Celator Pharmaceuticals aims to expand its product pipeline, focusing on new cancer therapies that leverage its proprietary delivery technology. The company intends to enter new markets in Europe and Asia by 2025, utilizing funds from its recent acquisition to bolster R&D initiatives. The acquisition by Jazz Pharmaceuticals is expected to facilitate access to broader distribution channels and resources, enhancing Celator's growth potential.

## Funding rounds

- Series D, Dec 15, 2011, $2.6M — Domain Associates, TL Ventures, Quaker Partners Management, Ventures West Capital, BDC Capital, Thomas, McNerney & Partners, GrowthWorks Capital
- Series D, Sep 1, 2010, $15M — Domain Associates, TL Ventures, Quaker Partners Management, Ventures West Capital, BDC Capital, Thomas, McNerney & Partners, GrowthWorks Capital
- Series C, Jul 29, 2008, $23M — Domain Associates, TL Ventures, Quaker Partners Management, Ventures West Capital, BDC Capital, GrowthWorks Capital
- Series B, Aug 10, 2007, $10M — Domain Associates, TL Ventures, Quaker Partners Management, Ventures West Capital, BDC Capital, GrowthWorks Capital, Hearthstone Investments Ltd.
- Series B, May 1, 2005, $40M — Domain Associates, TL Ventures, Quaker Partners Management, Ventures West Capital, BDC Capital, GrowthWorks Capital, Hearthstone Investments Ltd.
- Series A, Jan 28, 2003, $6.8M — Ventures West Capital, BDC Capital, GrowthWorks Capital

## Investors

- Ventures West Capital (https://capitalatlas.ai/funds/ventures-west-capital) — Series A, Series B, Series C, Series D
- BDC Capital (https://capitalatlas.ai/funds/bdc-capital) — Series A, Series B, Series C, Series D
- GrowthWorks Capital (https://capitalatlas.ai/funds/growthworks-capital) — Series A, Series B, Series C, Series D
- Domain Associates (https://capitalatlas.ai/funds/domain-associates) — Series B, Series C, Series D
- TL Ventures (https://capitalatlas.ai/funds/tl-ventures) — Series B, Series C, Series D
- Quaker Partners Management (https://capitalatlas.ai/funds/quaker-partners-management) — Series B, Series C, Series D
- Hearthstone Investments Ltd. — Series B
- Thomas, McNerney & Partners (https://capitalatlas.ai/funds/thomas-mcnerney-partners) — Series D